{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:10:52Z","timestamp":1793293852686,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-025-03570-x","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T03:48:13Z","timestamp":1747453693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of topical cyclosporine A in optimizing ocular surface and relieving dry eye symptoms after cataract surgery: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"45","author":[{"given":"Min","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"key":"3570_CR1","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1016\/S2214-109X(13)70113-X","volume":"44","author":"RR Bourne","year":"2013","unstructured":"Bourne RR et al (2013) Causes of vision loss worldwide, 1990\u20132010: a systematic analysis. Lancet Glob Health 44:e339\u2013e349. https:\/\/doi.org\/10.1016\/S2214-109X(13)70113-X","journal-title":"Lancet Glob Health"},{"key":"3570_CR2","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1177\/1120672120929958","volume":"3","author":"K Naderi","year":"2020","unstructured":"Naderi K, Gormley J, O\u2019Brart D (2020) Cataract surgery and dry eye disease: a review. Eur J Ophthalmol 3:840\u2013855. https:\/\/doi.org\/10.1177\/1120672120929958","journal-title":"Eur J Ophthalmol"},{"key":"3570_CR3","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s40123-022-00513-y","volume":"11","author":"M Miura","year":"2022","unstructured":"Miura M et al (2022) Prevalence and characteristics of dry eye disease after cataract surgery: a systematic review and meta-analysis. Ophthalmol Ther 11:1309\u20131332. https:\/\/doi.org\/10.1007\/s40123-022-00513-y","journal-title":"Ophthalmol Ther"},{"key":"3570_CR4","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1097\/ICO.0000000000001491","volume":"37","author":"E Iglesias","year":"2018","unstructured":"Iglesias E et al (2018) Epidemiology of persistent dry eye-like symptoms after cataract surgery. Cornea 37:893\u2013898. https:\/\/doi.org\/10.1097\/ICO.0000000000001491","journal-title":"Cornea"},{"key":"3570_CR5","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/j.jcrs.2017.10.033","volume":"43","author":"J Chuang","year":"2017","unstructured":"Chuang J et al (2017) Preoperative optimization of ocular surface disease before cataract surgery. J Cataract Refract Surg 43:1596\u20131607. https:\/\/doi.org\/10.1016\/j.jcrs.2017.10.033","journal-title":"J Cataract Refract Surg"},{"key":"3570_CR6","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.3390\/cells13151251","volume":"13","author":"C Song","year":"2024","unstructured":"Song C et al (2024) Diquafosol Improves Corneal Wound Healing by Inducing NGF Expression in an Experimental Dry Eye Model. Cells 13:1251. https:\/\/doi.org\/10.3390\/cells13151251","journal-title":"Cells"},{"key":"3570_CR7","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.ophtha.2017.07.010","volume":"124","author":"SC Pflugfelder","year":"2017","unstructured":"Pflugfelder SC, de Paiva CS (2017) The pathophysiology of dry eye disease: what we know and future directions for research. Ophthalmology 124:S4\u2013S13. https:\/\/doi.org\/10.1016\/j.ophtha.2017.07.010","journal-title":"Ophthalmology"},{"key":"3570_CR8","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1001\/archopht.126.8.1046","volume":"126","author":"HD Perry","year":"2008","unstructured":"Perry HD et al (2008) Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol 126:1046\u20131050. https:\/\/doi.org\/10.1001\/archopht.126.8.1046","journal-title":"Arch Ophthalmol"},{"key":"3570_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2147\/DDDT.S207743","volume":"14","author":"HI Tuan","year":"2020","unstructured":"Tuan HI, Chi SC, Kang YN (2020) An updated systematic review with meta-analysis of randomized trials on topical cyclosporin a for dry-eye disease. Drug Des Devel Ther 14:265\u2013274. https:\/\/doi.org\/10.2147\/DDDT.S207743","journal-title":"Drug Des Devel Ther"},{"key":"3570_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jtos.2014.12.006","volume":"13","author":"KH Wan","year":"2015","unstructured":"Wan KH, Chen LJ, Young AL (2015) Efficacy and safety of topical 0.05% cyclosporine eye drops in the treatment of dry eye syndrome: a systematic review and meta-analysis. Ocul Surf 13:213\u2013225. https:\/\/doi.org\/10.1016\/j.jtos.2014.12.006","journal-title":"Ocul Surf"},{"key":"3570_CR11","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.jcrs.2009.12.049","volume":"36","author":"ED Donnenfeld","year":"2010","unstructured":"Donnenfeld ED et al (2010) Cyclosporine 0.05% to improve visual outcomes after multifocal intraocular lens implantation. J Cataract Refract Surg 36:1095\u20131100. https:\/\/doi.org\/10.1016\/j.jcrs.2009.12.049","journal-title":"J Cataract Refract Surg"},{"key":"3570_CR12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3341\/kjo.2013.27.3.167","volume":"27","author":"YW Chung","year":"2013","unstructured":"Chung YW, Oh TH, Chung SK (2013) The effect of topical cyclosporine 0.05% on dry eye after cataract surgery. Korean J Ophthalmol 27:167\u2013171. https:\/\/doi.org\/10.3341\/kjo.2013.27.3.167","journal-title":"Korean J Ophthalmol"},{"key":"3570_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A et al (2009) (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700. https:\/\/doi.org\/10.1136\/bmj.b2700","journal-title":"BMJ"},{"key":"3570_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP et al (2011) (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"3570_CR15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924\u2013926. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"key":"3570_CR16","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1097\/MS9.0000000000001795","volume":"86","author":"H Ahmadi","year":"2024","unstructured":"Ahmadi H et al (2024) Evaluation of cyclosporine 0.05% and artificial tears for the management of dry eye disease following cataract surgery: a randomized controlled trial. Ann Med Surg (Lond) 86:1983\u20131988. https:\/\/doi.org\/10.1097\/MS9.0000000000001795","journal-title":"Ann Med Surg (Lond)"},{"key":"3570_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.clae.2015.07.003","volume":"39","author":"S Hamada","year":"2016","unstructured":"Hamada S et al (2016) Assessment of the effect of cyclosporine-A 0.05% emulsion on the ocular surface and corneal sensation following cataract surgery. Cont Lens Anterior Eye 39:15\u201319. https:\/\/doi.org\/10.1016\/j.clae.2015.07.003","journal-title":"Cont Lens Anterior Eye"},{"issue":"1","key":"3570_CR18","doi-asserted-by":"publisher","first-page":"e0245329","DOI":"10.1371\/journal.pone.0245329","volume":"16","author":"MS Kang","year":"2021","unstructured":"Kang MS, Shin J, Kwon JM, Huh J, Lee JE (2021) Efficacy of 0.05% cyclosporine A on the lipid layer and meibomian glands after cataract surgery: A randomized, double-masked study. Plos One 16(1):e0245329. https:\/\/doi.org\/10.1371\/journal.pone.0245329","journal-title":"Plos One"},{"key":"3570_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2174\/1874364101913010034","volume":"13","author":"S Ganesh","year":"2019","unstructured":"Ganesh S, Brar S, Bagare SN (2019) Topical cyclosporine (0.05%) for management of dry eyes in patients undergoing cataract surgery-a comparative study. Open Ophthalmol J 13:34\u201342. https:\/\/doi.org\/10.2174\/1874364101913010034","journal-title":"Open Ophthalmol J"},{"key":"3570_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.33142\/cmn.v1i1.7659","volume":"1","author":"Z Jin","year":"2023","unstructured":"Jin Z (2023) Observation on effect of 0.05% cyclosporine eye drops combined with 0.3% sodium hyaluronate eye drops on dry eyes after cataract surgery. Clin Med Nursing 1:12\u201315. https:\/\/doi.org\/10.33142\/cmn.v1i1.7659","journal-title":"Clin Med Nursing"},{"key":"3570_CR21","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.5455\/njppp.2018.8.1032328102018","volume":"8","author":"P Kudyar","year":"2018","unstructured":"Kudyar P et al (2018) Comparative evaluation of efficacy and safety of cyclosporine 0.1% add-on therapy with artificial tears (carboxymethylcellulose 0.5%) with artificial tears alone in post cataract surgery patients. Natl J Physiol Pharm Pharmacol 8:1685\u20131691. https:\/\/doi.org\/10.5455\/njppp.2018.8.1032328102018","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"3570_CR22","first-page":"49","volume":"6","author":"P Kudyar","year":"2018","unstructured":"Kudyar P, Khajuria V, Gupta BM (2018) Comparison of efficacy of treatment with cyclosporine 0.1% add on therapy with artificial tears (carboxy methyl cellulose 0.5%) & artificial tears alone on dry eye parameters in post cataract surgery patients. J Adv Med Dent Scie Res 6:49\u201353","journal-title":"J Adv Med Dent Scie Res"},{"key":"3570_CR23","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.3341\/jkos.2013.54.7.1013","volume":"54","author":"AR Yoo","year":"2013","unstructured":"Yoo AR et al (2013) Effects of cyclosporine 0.05% ophthalmic emulsion to improve reduction of tear production after cataract surgery. J Korean Ophthalmol Soc 54:1013\u20131018. https:\/\/doi.org\/10.3341\/jkos.2013.54.7.1013","journal-title":"J Korean Ophthalmol Soc"},{"key":"3570_CR24","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP et al (2017) TFOS DEWS II definition and classification report. Ocul Surf 15:276\u2013283. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.008","journal-title":"Ocul Surf"},{"key":"3570_CR25","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1097\/ICO.0b013e3181a16578","volume":"28","author":"ML Massingale","year":"2009","unstructured":"Massingale ML et al (2009) Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea 28:1023\u20131027. https:\/\/doi.org\/10.1097\/ICO.0b013e3181a16578","journal-title":"Cornea"},{"key":"3570_CR26","first-page":"2283","volume":"42","author":"A Solomon","year":"2001","unstructured":"Solomon A et al (2001) Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci 42:2283\u20132292","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3570_CR27","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1167\/iovs.18-25822","volume":"60","author":"A Di Zazzo","year":"2019","unstructured":"Di Zazzo A et al (2019) InflammAging at ocular surface: clinical and biomolecular analyses in healthy volunteers. Invest Ophthalmol Vis Sci 60:1769\u20131775. https:\/\/doi.org\/10.1167\/iovs.18-25822","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3570_CR28","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/09273948.2021.1906908","volume":"29","author":"M Rolando","year":"2021","unstructured":"Rolando M, Barabino S (2021) The subtle role of para-inflammation in modulating the progression of dry eye disease. Ocul Immunol Inflamm 29:811\u2013816. https:\/\/doi.org\/10.1080\/09273948.2021.1906908","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"3570_CR29","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1056\/NEJM199101313240501","volume":"324","author":"CN Ellis","year":"1991","unstructured":"Ellis CN et al (1991) Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 324(5):277\u2013284. https:\/\/doi.org\/10.1056\/NEJM199101313240501","journal-title":"N Engl J Med"},{"key":"3570_CR30","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","volume":"330","author":"S Lichtiger","year":"1994","unstructured":"Lichtiger S et al (1994) Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330:1841\u20131845. https:\/\/doi.org\/10.1056\/NEJM199406303302601","journal-title":"N Engl J Med"},{"key":"3570_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001083","author":"G Wells","year":"1998","unstructured":"Wells G et al (1998) Cyclosporine for treating rheumatoid arthritis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD001083","journal-title":"Cochrane Database Syst Rev"},{"key":"3570_CR32","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.1167\/iovs.13-11681","volume":"54","author":"J Gao","year":"2013","unstructured":"Gao J et al (2013) Mitochondrial permeability transition pore in inflammatory apoptosis of human conjunctival epithelial cells and T cells: effect of cyclosporin A. Invest Ophthalmol Vis Sci 54:4717\u20134133. https:\/\/doi.org\/10.1167\/iovs.13-11681","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3570_CR33","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1001\/archopht.120.3.330","volume":"120","author":"KS Kunert","year":"2002","unstructured":"Kunert KS, Tisdale AS, Gipson IK (2002) Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol 120:330\u2013337. https:\/\/doi.org\/10.1001\/archopht.120.3.330","journal-title":"Arch Ophthalmol"},{"key":"3570_CR34","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1089\/jop.2018.0005","volume":"34","author":"I Moon","year":"2018","unstructured":"Moon I et al (2018) Comparison of ocular surface mucin expression after topical ophthalmic drug administration in dry eye-induced mouse model. J Ocul Pharmacol Ther 34:612\u2013620. https:\/\/doi.org\/10.1089\/jop.2018.0005","journal-title":"J Ocul Pharmacol Ther"},{"key":"3570_CR35","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.2147\/OPTH.S279051","volume":"14","author":"LM Periman","year":"2020","unstructured":"Periman LM, Mah FS, Karpecki PM (2020) A review of the mechanism of action of cyclosporine a: the role of cyclosporine a in dry eye disease and recent formulation developments. Clin Ophthalmol 14:4187\u20134200. https:\/\/doi.org\/10.2147\/OPTH.S279051","journal-title":"Clin Ophthalmol"},{"key":"3570_CR36","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000003561","author":"A Di Zazzo","year":"2024","unstructured":"Di Zazzo A et al (2024) Prophylactic Therapy for Long-Term Ocular Discomfort After Cataract Surgery. Cornea. https:\/\/doi.org\/10.1097\/ICO.0000000000003561","journal-title":"Cornea"},{"key":"3570_CR37","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.2147\/OPTH.S325659","volume":"15","author":"JA Hovanesian","year":"2021","unstructured":"Hovanesian JA et al (2021) Effect of cyclosporine 0.09% treatment on accuracy of preoperative biometry and higher order aberrations in dry eye patients undergoing cataract surgery. Clin Ophthalmol 15:3679\u20133686. https:\/\/doi.org\/10.2147\/OPTH.S325659","journal-title":"Clin Ophthalmol"},{"key":"3570_CR38","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/j.jcrs.0000000000001423","volume":"50","author":"EK Akpek","year":"2024","unstructured":"Akpek EK et al (2024) Efficacy of a new water-free topical cyclosporine 0.1% solution for optimizing the ocular surface in patients with dry eye and cataract. J Cataract Refract Surg 50:644\u2013650. https:\/\/doi.org\/10.1097\/j.jcrs.0000000000001423","journal-title":"J Cataract Refract Surg"},{"key":"3570_CR39","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2024.0169","author":"Y Aleksander-Ivanov","year":"2025","unstructured":"Aleksander-Ivanov Y et al (2025) Safety and Efficacy of 0.1% Cyclosporine Solutions in Dry Eye Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. J Ocul Pharmacol Ther. https:\/\/doi.org\/10.1089\/jop.2024.0169","journal-title":"J Ocul Pharmacol Ther"},{"key":"3570_CR40","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3341\/jkos.2023.64.11.987","volume":"64","author":"H Han","year":"2023","unstructured":"Han H, Choi S (2023) Comparison of the Effects of 0.05% and 0.1% Cyclosporine for Dry Eye Syndrome Patients after Cataract Surgery. J Korean Ophthalmol Soc 64:987\u20131000. https:\/\/doi.org\/10.3341\/jkos.2023.64.11.987","journal-title":"J Korean Ophthalmol Soc"},{"key":"3570_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010051.pub2","author":"CS de Paiva","year":"2019","unstructured":"de Paiva CS et al (2019) Topical cyclosporine a therapy for dry eye syndrome. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD010051.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"3570_CR42","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3341\/jkos.2019.60.9.821","volume":"60","author":"JY Park","year":"2019","unstructured":"Park JY et al (2019) Effectiveness of cyclosporine-steroid treatment after cataract surgery according to dry eye severity. J Korean Ophthalmol Soc 60:821\u2013828. https:\/\/doi.org\/10.3341\/jkos.2019.60.9.821","journal-title":"J Korean Ophthalmol Soc"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03570-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03570-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03570-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:05:29Z","timestamp":1766167529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03570-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3570"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03570-x","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable for meta-analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"201"}}